B.Riley initiates Capricor Therapeutics stock with buy rating

B.Riley initiated coverage on Capricor Therapeutics (CAPR) with a Buy rating and $21 price target, citing Deramiocel's potential as the first therapy for Duchenne Muscular Dystrophy-cardiomyopathy, supported by positive Phase II data showing cardiac function preservation. While the FDA will not require an Advisory Committee meeting for the Priority Review, set for an August 31, 2025 action date, analyst sentiment is mixed regarding regulatory risk: B.Riley and H.C. Wainwright downplay concerns over recent FDA personnel changes, projecting significant post-approval revenue, while Oppenheimer remains cautious, lowering its price target due to review process concerns.

Analysis

Capricor Therapeutics (CAPR) presents a high-stakes, catalyst-driven investment profile centered on its lead drug candidate, Deramiocel. The divergence in recent analyst ratings encapsulates the core debate: B.Riley and H.C. Wainwright champion the bull case, initiating and maintaining Buy ratings, respectively, while Oppenheimer expresses caution by lowering its price target. The bullish thesis is underpinned by Deramiocel's potential to be the first-ever approved therapy for Duchenne Muscular Dystrophy (DMD)-cardiomyopathy, a major cause of mortality in DMD patients. This is supported by Phase II data showing clinically meaningful preservation of cardiac function, including left ventricular ejection fraction improvements of 1.9% at 24 months and 1.2% at 36 months. Key positive regulatory signals include the FDA's decision to grant Priority Review and waive the need for an Advisory Committee meeting, which often de-risks the path to approval. B.Riley projects a rapid commercial launch, estimating $25-$50 million in revenue within a single quarter. Conversely, the primary risk, articulated by Oppenheimer, stems from regulatory uncertainty following the unexpected administrative leave of key FDA officials, which could impact the review process ahead of the August 31, 2025 PDUFA action date. This creates a clear binary outcome for the stock, with analyst price targets ranging from $22 to $77, indicating substantial potential upside from its current $10.05 price if approval is secured.

Key Decisions for Investors

• Investors should view Capricor as a high-risk, high-reward biotech play, with its value almost entirely dependent on the binary outcome of the FDA's decision on Deramiocel by its August 2025 PDUFA date.
• The primary risk factor to monitor is regulatory news flow; any further updates on the FDA's review process or the impact of recent personnel changes will be critical in assessing the probability of approval.
• Given the waiver of an Advisory Committee meeting and strong clinical data, bullish investors may consider the divergence in analyst opinions a buying opportunity, but should size positions to reflect the significant downside risk of a potential rejection.
• Investors should evaluate the company's projected commercial launch, where an estimated 100-200 patient base could generate $25-$50 million in initial quarterly revenue, as a key metric for post-approval valuation.